Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

Olsson, Sven-Eric ; Villa, Luisa L. ; Costa, Ronaldo L. R. ; Petta, Carlos A. ; Andrade, Rosires P. ; Malm, Christian ; Iversen, Ole-Erik ; Hoye, John ; Steinwall, Margareta LU and Riis-Johannessen, Grete , et al. (2007) In Vaccine 25(26). p.4931-4939
Abstract
Background: The duration of protection afforded by vaccines represents a critical test of their utility as public health interventions. Some vaccines induce long-term immunity, while others require booster doses. Vaccines that induce long-term protection are usually characterized by the generation of immune memory. Recent trials of a quadrivalent (types 6, 11, 16, 18) human papillomavirus (HPV) vaccine have demonstrated high efficacy through 5 years of follow-up. We evaluated the extent to which the vaccine is able to generate HPV type-specific immune memory. Methods: A total of 552, 16-23-year-old women were enrolled in a double-blind, placebo-controlled study. At enrollment, subjects were randomized in a 1:1 ratio to receive three-dose... (More)
Background: The duration of protection afforded by vaccines represents a critical test of their utility as public health interventions. Some vaccines induce long-term immunity, while others require booster doses. Vaccines that induce long-term protection are usually characterized by the generation of immune memory. Recent trials of a quadrivalent (types 6, 11, 16, 18) human papillomavirus (HPV) vaccine have demonstrated high efficacy through 5 years of follow-up. We evaluated the extent to which the vaccine is able to generate HPV type-specific immune memory. Methods: A total of 552, 16-23-year-old women were enrolled in a double-blind, placebo-controlled study. At enrollment, subjects were randomized in a 1:1 ratio to receive three-dose regimens of quadrivalent HPV vaccine or placebo with 3 years' follow-up. A subset of 241 subjects (n = 114 in the quadrivalent HPV vaccine group and n = 127 in the placebo group) underwent 2 further years of follow-up. All extension subjects received quadrivalent HPV vaccine at month 60 to examine the extent of immune memory in response to the primary vaccination series. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
genital warts, cervical intraepithelial neoplasia (CIN), virus-like particles, human papillomavirus, prophylactic vaccine, clinical trial, cervical, cancer
in
Vaccine
volume
25
issue
26
pages
4931 - 4939
publisher
Elsevier
external identifiers
  • wos:000247547400009
  • scopus:34249689698
  • pmid:17499406
ISSN
1873-2518
DOI
10.1016/j.vaccine.2007.03.049
language
English
LU publication?
yes
id
79ca810a-ae2f-420d-b7bc-d8d5d1a08c06 (old id 647908)
date added to LUP
2016-04-01 12:37:58
date last changed
2022-04-21 18:05:56
@article{79ca810a-ae2f-420d-b7bc-d8d5d1a08c06,
  abstract     = {{Background: The duration of protection afforded by vaccines represents a critical test of their utility as public health interventions. Some vaccines induce long-term immunity, while others require booster doses. Vaccines that induce long-term protection are usually characterized by the generation of immune memory. Recent trials of a quadrivalent (types 6, 11, 16, 18) human papillomavirus (HPV) vaccine have demonstrated high efficacy through 5 years of follow-up. We evaluated the extent to which the vaccine is able to generate HPV type-specific immune memory. Methods: A total of 552, 16-23-year-old women were enrolled in a double-blind, placebo-controlled study. At enrollment, subjects were randomized in a 1:1 ratio to receive three-dose regimens of quadrivalent HPV vaccine or placebo with 3 years' follow-up. A subset of 241 subjects (n = 114 in the quadrivalent HPV vaccine group and n = 127 in the placebo group) underwent 2 further years of follow-up. All extension subjects received quadrivalent HPV vaccine at month 60 to examine the extent of immune memory in response to the primary vaccination series.}},
  author       = {{Olsson, Sven-Eric and Villa, Luisa L. and Costa, Ronaldo L. R. and Petta, Carlos A. and Andrade, Rosires P. and Malm, Christian and Iversen, Ole-Erik and Hoye, John and Steinwall, Margareta and Riis-Johannessen, Grete and Andersson-Ellstrom, Agneta and Elfgren, Kristina and von Krogh, Geo and Lehtinen, Matti and Paavonen, Jorma and Tamms, Gretchen M. and Giacoletti, Katherine and Lupinacci, Lisa and Esser, Mark T. and Vuocolo, Scott C. and Saah, Alfred J. and Barr, Eliav}},
  issn         = {{1873-2518}},
  keywords     = {{genital warts; cervical intraepithelial neoplasia (CIN); virus-like particles; human papillomavirus; prophylactic vaccine; clinical trial; cervical; cancer}},
  language     = {{eng}},
  number       = {{26}},
  pages        = {{4931--4939}},
  publisher    = {{Elsevier}},
  series       = {{Vaccine}},
  title        = {{Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine}},
  url          = {{http://dx.doi.org/10.1016/j.vaccine.2007.03.049}},
  doi          = {{10.1016/j.vaccine.2007.03.049}},
  volume       = {{25}},
  year         = {{2007}},
}